Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.68 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148981 | 1.00 | RORC (0.68) | RORCTACR1PDE4BNAMPTGPR119 | |
| SCHEMBL20149241 | 0.88 | RORC (0.57) | RORCTACR1PDE4BNAMPTUSP30 | |
| SCHEMBL20148976 | 0.88 | RORC (0.57) | RORCTACR1PDE4BNAMPTUSP30 | |
| SCHEMBL7890064 | 0.87 | PDE4B (0.58) | RORCTACR1PDE4BNAMPTUSP30 | |
| SCHEMBL20148899 | 0.86 | RORC (0.72) | RORCTACR1PDE4BNAMPTGPR119 | |
| SCHEMBL6917693 | 0.86 | RORC (0.52) | RORCTACR1PDE4BNAMPTKCNK3 | |
| SCHEMBL1992736 | 0.86 | RORC (0.52) | RORCTACR1PDE4BNAMPTKCNK3 | |
| SCHEMBL30912445 | 0.85 | RORC (0.54) | RORCTACR1PDE4BNAMPTKCNK3 | |
| SCHEMBL19459113 | 0.85 | RORC (0.54) | RORCTACR1PDE4BNAMPTKCNK3 | |
| SCHEMBL23951798 | 0.85 | RORC (0.65) | RORCTACR1PDE4BNAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3538522-A1 | ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | RORC 2/4885TACR1 1939/4885PDE4B 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.